Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116207 · ClinicalTrials.gov registry record · Phase 3
An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes
A Phase 3 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 3
- Development phase
- 44
- Enrollment target
NCT00116207 is a Phase 3 study that has completed, run by University of Michigan. The registered enrollment target is 44 participants.
The verdict
NCT00116207, a Phase 3 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 44 participants
- Enrollment target
Study Summary
The focus of this project is cardiovascular diabetic autonomic neuropathy (DAN). DAN affects the nerves that control heart rate and blood flow to the heart in people with diabetes. DAN may cause problems with the rhythm of the heartbeat or decrease blood flow to the heart. Three medications will be tested for their effectiveness in DAN.
Interventions
- DRUG ORAL ANTIOXIDANT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2000-01 |
| Est. Completion | 2009-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116207
The ClinicalTrials.gov registry entry for NCT00116207 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ORAL ANTIOXIDANT is the first listed.
NCT00116207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116207 about?
NCT00116207 is a clinical study titled "An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes". The focus of this project is cardiovascular diabetic autonomic neuropathy (DAN). DAN affects the nerves that control heart rate and blood flow to the heart in people with diabetes. DAN may cause problems with the rhythm of the heartbeat or decrease blood flow to the heart. Three medications will be ...
What is the current status of trial NCT00116207?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 44 participants. The study started on 2000-01. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00116207?
The interventions under investigation include: ORAL ANTIOXIDANT (DRUG).
Who is sponsoring clinical trial NCT00116207?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.